imipramine has been researched along with Coronary Disease in 11 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
Excerpt | Relevance | Reference |
---|---|---|
"Imipramine improved the symptoms of patients with chest pain and normal coronary angiograms, possibly through a visceral analgesic effect." | 9.07 | Imipramine in patients with chest pain despite normal coronary angiograms. ( Black, BC; Cannon, RO; Geraci, MF; Gracely, RH; Mincemoyer, R; Quyyumi, AA; Smith, WB; Stine, AM; Uhde, TW; Waclawiw, MA, 1994) |
"Imipramine improved the symptoms of patients with chest pain and normal coronary angiograms, possibly through a visceral analgesic effect." | 5.07 | Imipramine in patients with chest pain despite normal coronary angiograms. ( Black, BC; Cannon, RO; Geraci, MF; Gracely, RH; Mincemoyer, R; Quyyumi, AA; Smith, WB; Stine, AM; Uhde, TW; Waclawiw, MA, 1994) |
"The authors report on 12 men with ischemic heart disease who developed secondary depression following myocardial infarction or coronary artery bypass-graft surgery and were treated with imipramine hydrochloride for 4 weeks." | 3.66 | Cardiovascular and antidepressant effects of imipramine in the treatment of secondary depression in patients with ischemic heart disease. ( Barnes, R; Gumbrecht, G; Raskind, M; Veith, R, 1982) |
"Amineptine, however, was ineffective in preventing reperfusion arrhythmias even in a high concentration, this agent did not decrease heart rate." | 1.27 | Comparison of the effect of antidepressant drugs on arrhythmias in the isolated rat heart subjected to myocardial ischaemia and reperfusion. ( Bril, A; Rochette, L, 1987) |
"We evaluated the ability of the Lown arrhythmia grading system to predict death in 400 patients who were convalescing from acute myocardial infarction." | 1.26 | Shortcomings of the Lown grading system for observational or experimental studies in ischemic heart disease. ( Bigger, JT; Weld, FM, 1980) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 9 (81.82) | 18.7374 |
1990's | 2 (18.18) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Raskind, M | 1 |
Veith, R | 1 |
Barnes, R | 1 |
Gumbrecht, G | 1 |
Zaĭtsev, VP | 1 |
Kol'tsova, TI | 1 |
Bigger, JT | 2 |
Weld, FM | 2 |
Cannon, RO | 1 |
Quyyumi, AA | 1 |
Mincemoyer, R | 1 |
Stine, AM | 1 |
Gracely, RH | 1 |
Smith, WB | 1 |
Geraci, MF | 1 |
Black, BC | 1 |
Uhde, TW | 1 |
Waclawiw, MA | 1 |
Sparks, DL | 1 |
Danner, FW | 1 |
Davis, DG | 1 |
Hackney, C | 1 |
Landers, T | 1 |
Coyne, CM | 1 |
Biamino, G | 1 |
Fenner, H | 1 |
Neye, J | 1 |
Schuren, KP | 1 |
Ramdohr, B | 1 |
Krause, EG | 1 |
Härtwig, A | 1 |
Rabitzsch, G | 1 |
Bril, A | 1 |
Rochette, L | 1 |
Cunescu, V | 1 |
Pârvu, V | 1 |
Moccetti, T | 1 |
Lichtlen, P | 1 |
Casaccia, M | 1 |
Halter, J | 1 |
Mohr, P | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Pain Measurement in Healthy Volunteers[NCT00001597] | 40 participants | Observational | 1997-03-31 | Completed | |||
Psychophysiological Interactions in Non-Cardiac Chest Pain[NCT00005575] | Phase 3 | 0 participants | Interventional | 1999-01-31 | Completed | ||
WISE Ancillary Study Data Analyses: Efficacy of Hormone Replacement on Myocardial Ischemia in Postmenopausal Women With Normal/Minimal Coronary Artery Disease: Data Analysis[NCT00600106] | 37 participants (Actual) | Interventional | 1999-12-31 | Completed | |||
A Controlled, Randomized, Double-Blind Trial of Sertraline in Patients With Frontal Lobe Dementia (FLD)[NCT00001777] | Phase 1 | 30 participants | Interventional | 1997-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of endothelial dysfunction.~Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter [diameter after cuff deflation - baseline diameter / baseline diameter) x 100]." (NCT00600106)
Timeframe: Baseline
Intervention | percentage of pre-stimulus diameter (Mean) |
---|---|
Hormone Replacement Therapy | 8.2 |
Placebo | 8.8 |
"Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of vasomotor function.~Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter [diameter after cuff deflation - baseline diameter / baseline diameter) x 100]." (NCT00600106)
Timeframe: 12 weeks
Intervention | percentage of pre-stimulus diameter (Mean) |
---|---|
Hormone Replacement Therapy | 8.8 |
Placebo | 7.3 |
Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-[average of rest and recovery periods]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio >20% from rest, and a lower value is considered indicative of greater ischemia. (NCT00600106)
Timeframe: 12 weeks
Intervention | percent change in PCR/ATP ratio (Mean) |
---|---|
Hormone Replacement Therapy | -7.7 |
Placebo | 1.1 |
Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-[average of rest and recovery periods]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio >20% from rest, and a lower value is considered indicative of greater ischemia. (NCT00600106)
Timeframe: Baseline
Intervention | percent changed in PCR/ATP ratio (Mean) |
---|---|
Hormone Replacement Therapy | -13.8 |
Placebo | -7.0 |
"Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.~In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (>1.0 mm horizontal / downsloping or >1.5 upsloping ST segment depression measured 0.08 msec after the J point)." (NCT00600106)
Timeframe: Baseline
Intervention | mm (Mean) |
---|---|
Hormone Replacement Therapy | -0.79 |
Placebo | -0.79 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. (NCT00600106)
Timeframe: Baseline
Intervention | metabolism equivalents (Mean) |
---|---|
Hormone Replacement Therapy | 6.1 |
Placebo | 5.8 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. (NCT00600106)
Timeframe: Exit (12 weeks)
Intervention | metabolism equivalents (Mean) |
---|---|
Hormone Replacement Therapy | 6.1 |
Placebo | 5.4 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on. (NCT00600106)
Timeframe: Baseline
Intervention | metabolism equivalents (Mean) |
---|---|
Hormone Replacement Therapy | 5.4 |
Placebo | 5.4 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on. (NCT00600106)
Timeframe: Exit at 12 weeks
Intervention | metabolism equivalents (Mean) |
---|---|
Hormone Replacement Therapy | 6.1 |
Placebo | 5.4 |
"Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.~In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (>1.0 mm horizontal / downsloping or >1.5 upsloping ST segment depression measured 0.08 msec after the J point)." (NCT00600106)
Timeframe: Exit (12 weeks)
Intervention | mm (Mean) |
---|---|
Hormone Replacement Therapy | -1.05 |
Placebo | -0.63 |
"Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.~Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT00600106)
Timeframe: 12 weeks
Intervention | units on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Physical functioning | Role-physical | Role-emotional | Bodily pain | General health | Mental health | Vitality | Social functioning | |
Hormone Replacement Therapy | 59.4 | 58.8 | 76.5 | 54.5 | 55.2 | 66.4 | 35.6 | 59.4 |
Placebo | 44.4 | 25.0 | 66.7 | 41.5 | 57.2 | 69.3 | 41.2 | 56.1 |
"Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.~Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT00600106)
Timeframe: Baseline
Intervention | units on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Physical functioning | Role-physical | Role-emotional | Bodily pain | General health | Mental health | Vitality | Social functioning | |
Hormone Replacement Therapy | 60.8 | 54.2 | 70.3 | 53.3 | 55.4 | 66.7 | 35.6 | 59.4 |
Placebo | 43.8 | 37.3 | 66.7 | 42.1 | 57.4 | 65.7 | 42.9 | 53.2 |
Quality of life assessed by menopausal symptoms and psychological questionnaires (NCT00600106)
Timeframe: 12 weeks
Intervention | percent of participants (Number) | ||||
---|---|---|---|---|---|
Hot flushes or flashing | Poor memory | Change in sexual desire | Vaginal dryness | Avoiding intimacy | |
Hormone Replacement Therapy | 41 | 59 | 35 | 35 | 24 |
Placebo | 89 | 78 | 67 | 67 | 56 |
Quality of life assessed by menopausal symptoms and psychological questionnaires (NCT00600106)
Timeframe: Baseline
Intervention | percent of participants (Number) | ||||
---|---|---|---|---|---|
Hot flushes or flashing | Poor memory | Change in sexual desire | Vaginal dryness | Avoiding intimacy | |
Hormone Replacement Therapy | 89 | 76 | 50 | 44 | 39 |
Placebo | 68 | 53 | 37 | 58 | 37 |
2 reviews available for imipramine and Coronary Disease
Article | Year |
---|---|
Drugs and sudden cardiac death.
Topics: Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Coronary Disease; Death, Sudden; Diet Fads; | 1982 |
[Drug iatrogenesis in cardiology].
Topics: Antidepressive Agents; Antihypertensive Agents; Appetite Depressants; Blood Coagulation Disorders; C | 1971 |
2 trials available for imipramine and Coronary Disease
Article | Year |
---|---|
[Comparative effectiveness of tricyclic antidepressants in the treatment of psychic changes in ischemic heart disease].
Topics: Adult; Affective Symptoms; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Clinical Trials as | 1980 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
7 other studies available for imipramine and Coronary Disease
Article | Year |
---|---|
Cardiovascular and antidepressant effects of imipramine in the treatment of secondary depression in patients with ischemic heart disease.
Topics: Adult; Aged; Blood Pressure; Cardiac Complexes, Premature; Coronary Artery Bypass; Coronary Disease; | 1982 |
Shortcomings of the Lown grading system for observational or experimental studies in ischemic heart disease.
Topics: Arrhythmias, Cardiac; Coronary Disease; Electrocardiography; Heart Ventricles; Humans; Imipramine; P | 1980 |
Neurochemical and histopathologic alterations characteristic of Pick's disease in a non-demented individual.
Topics: Acetylcholinesterase; Aged; Brain; Carrier Proteins; Choline O-Acetyltransferase; Cognition; Coronar | 1994 |
Comparative in vitro and in vivo studies on the effects of tricyclic antidepressants on myocardial contractility.
Topics: Acridines; Animals; Antidepressive Agents, Tricyclic; Cats; Chemical Phenomena; Chemistry; Coronary | 1975 |
On the release of glycogen phosphorylase from heart muscle: effect of substrate depletion, ischemia and of imipramine.
Topics: Animals; Coronary Disease; Creatine Kinase; Glucose; Heart; Imipramine; Insulin; Kinetics; Myocardia | 1989 |
Comparison of the effect of antidepressant drugs on arrhythmias in the isolated rat heart subjected to myocardial ischaemia and reperfusion.
Topics: Animals; Anti-Arrhythmia Agents; Antidepressive Agents; Arrhythmias, Cardiac; Coronary Disease; Dibe | 1987 |
[Cardiac toxicity of tricyclic antidepressants].
Topics: Adult; Antidepressive Agents; Arrhythmias, Cardiac; Coronary Disease; Electrocardiography; Female; H | 1972 |